Clinical Significance of Peroxisome Proliferator-Activated Receptor gamma and TRAP220 in Patients with Operable Colorectal Cancer.
- Author:
Kyung A KWON
1
;
Jeanho YUN
;
Sung Yong OH
;
Bong Gun SEO
;
Suee LEE
;
Ji Hyun LEE
;
Sung Hyun KIM
;
Hong Jo CHOI
;
Mee Sook ROH
;
Hyo Jin KIM
Author Information
- Publication Type:Original Article
- Keywords: PPARgamma; Mediator complex subunit 1; Colorectal neoplasms
- MeSH: Colorectal Neoplasms*; Disease-Free Survival; Follow-Up Studies; Humans; Immunohistochemistry; Lipid Metabolism; Lymph Nodes; Mediator Complex Subunit 1*; Multivariate Analysis; Neoplasm Metastasis; Peroxisomes*; PPAR gamma*; Prognosis; Thyroid Gland
- From:Cancer Research and Treatment 2016;48(1):198-207
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. Thyroid hormone receptor-associated proteins 220 (TRAP220) is an essential component of the TRAP/Mediator complex. The objective of this study was to clarify whether PPARgamma or TRAP220 are significant prognostic markers in resectable colorectal cancer (CRC). MATERIALS AND METHODS: A total of 399 patients who underwent curative resection for CRC were enrolled. We investigated the presence of PPARgamma and TARP220 in CRC tissues and adjacent normal tissues by immunohistochemistry. Correlation between the expression of these factors and clinicopathologic features and survival was investigated. RESULTS: Median age of the patients was 63 years (range, 22 to 87 years), and median follow-up duration 61.1 months (range, 2 to 114 months). PPARgamma and TRAP220 expression showed significant correlation with depth of invasion (p=0.013 and p=0.001, respectively). Expression of TRAP220 also showed association with lymph node metastasis and TNM stage (p=0.001). Compared with patients with TRAP220 negative tumors, patients with TRAP220 positive tumors had longer 5-year disease-free survival (DFS) tendency (p=0.051). Patients who were PPARgamma positive combined with TRAP220 positive had a better 5-year DFS (64.8% vs. 79.3%, p=0.013). In multivariate analysis expression of both PPARgamma and TRAP220 significantly affected DFS (hazard ratio, 0.620; 95% confidence interval, 0.379 to 0.997; p=0.048). CONCLUSION: TRAP220 may be a valuable marker for nodal metastasis and TNM stage. Tumor co-expression of PPARgamma and TRAP220 represents a biomarker for good prognosis in CRC patients.
